Navigation Links
BBM Announces Offer to Acquire YM BioSciences Inc.
Date:11/13/2008

for at least 90% of the shares of YMI Corporation, subject to confirmation by YMI that it has not entered into any agreement to sell equity securities or incur any indebtedness since the date of its most recently published financial statements, declared any cash dividends nor entered into any commercial or other agreements outside of the ordinary course of business during that period, and that it will not do so going forward.

Andrew Limpert, interim CEO of BBM stated: "We believe a combined BBM and YMI will make a powerful Biotech combination. The scientific synergies and collective management skills, with the recent addition of Dr. Hirschman to BBM, combined with the already impressive team at YMI will create significant value creation for all stake holders involved. We look forward to working with YMI and also on future acquisitions of promising pharmaceuticals." Dr. Shalom Z. Hirschman, consultant to BBM leading its acquisition program, added, "A creative approach to the clinical development of YMI's most promising chemotherapeutic agents can add great benefit to the treatment of particular neoplasms and enhance shareholder value. The science underlying YMI's products meshes very well with the technology recently acquired by BBM."

The full text of the offer letter was filed by BBM in a Form 8-K today.

About BBM Holdings:

BBM Holdings (OTC Bulletin Board: BBMO) has been exploring acquisition possibilities. It was formerly a telecommunications engineering and service company.

This press release contains statements that constitute "forward-looking statements" as that term is defined in the Securities Reform Act of 1995 (the "Reform Act"). Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements. Factors that may cause or contribute to such differences include, among other things, failure of our acquisition program, inability to
'/>"/>

SOURCE BBM Holdings
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Covanta Announces Amended Terms for its Acquisition of Two Biomass Energy Facilities in Maine
2. Posit Science(R) Corporation Announces the Release of InSight(TM) 1.1
3. MedImmune Announces Zook as President
4. Yongye Biotechnology Announces Record Third Quarter Results
5. Human Pheromone Sciences Announces Third Quarter Results
6. WuXi PharmaTech Announces Third Quarter 2008 Results
7. Telik Announces New TRAP Drug Discovery Agreement
8. SciQuest Announces Strategic Alliance with QIAGEN
9. Spectral announces third quarter 2008 results
10. AMDL Announces Preliminary Third Quarter Earnings; Revises 2008 Guidance
11. Metabolex Announces Positive Results From Phase 1a Clinical Trial of MBX-2982
Post Your Comments:
*Name:
*Comment:
*Email: